From: What do we know about managing Dupuytren’s disease cost-effectively?
Yes | No | Not Applicable | ||
---|---|---|---|---|
CHEERS reporting item | ||||
1 | Title | 4 | ||
2 | Abstract | 4 | ||
3 | Background and objectives | 4 | ||
4 | Target population and subgroups | 4 | ||
5 | Setting and location | 4 | ||
6 | Study perspective | 4 | ||
7 | Comparators | 4 | ||
8 | Time horizon | 4 | ||
9 | Discount rate | 3 | 1 | |
10 | Choice of health outcomes | 4 | ||
11a | Measurement of effectiveness (single study-based estimates) | 4 | ||
11b | Measurement of effectiveness (synthesis-based estimates) | 4 | ||
12 | Measurement and valuation of preference-based outcomes | 4 | ||
13a | Estimating resources and costs (single study-based economic evaluation) | 4 | ||
13b | Estimating resources and costs (model-based economic evaluation) | 4 | ||
14 | Currency, price date and conversion | 4 | ||
15 | Choice of model | 4 | ||
16 | Assumptions | 4 | ||
17 | Analytic method | 4 | ||
18 | Study parameters | 4 | ||
19 | Incremental costs and outcomes | 3 | 1 | |
20a | Characterising uncertainty (single study-based economic evaluation) | 4 | ||
20b | Characterising uncertainty (model-based economic evaluation) | 3 | 1 | |
21 | Characterising heterogeneity | 1 | 3 | |
22 | Study findings, limitations, generalisability and current knowledge | 4 | ||
23 | Source of funding | 3 | 1 | |
24 | Conflicts of interest | 3 | 1 |